Indivior Pharmaceuticals, Inc. 8K

Supernus and Indivior announced a tax-free, stock-for-stock merger of equals to create Supernus, Inc., a $2.2 billion-revenue CNS biopharmaceutical leader, with a 1.5401 Indivior share exchange ratio for each Supernus share, a $1 billion pre-closing dividend to Indivior shareholders, and expected annual cost synergies of at least $125 million, targeted to close in Q4 2026 pending approvals.

Supernus Pharmaceuticals and Indivior have agreed to a tax-free, all-stock merger of equals to form a combined central nervous system (CNS) biopharmaceutical company, Supernus, Inc., headquartered in Rockville, Maryland, with a diversified portfolio of 11 commercial medicines and pro forma net revenue of approximately $2.2 billion for the twelve months ended June 30, 2026; under the agreement, each Supernus share will be exchanged for 1.5401 Indivior shares, pre-closing Indivior stockholders will receive a $1 billion special dividend funded with additional debt, post-closing ownership will be approximately 56.5% Indivior holders and 43.5% Supernus holders, governance will be split 4/4 between the legacy boards with Tony Kingsley as non-executive chair and Jack Khattar as President and CEO, and the companies expect at least $125 million in annual cost synergies, subject to shareholder and regulatory approvals with a targeted closing in Q4 2026.

Filing Facts

CIK

1625297

Ticker

INDV

Form

8K

Source Type

fda

Accession

0001193125-26-329618

Alert Tier

8